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Abstract
Background: Drug combination therapy is commonly used in clinical practice. Many methods including Bliss 
independence method have been proposed for drug combination design based on simulations models or 
experiments. Although Bliss independence method can help to solve the drug combination design problem when 
there are only a small number of combinations, as the number of combinations increases, it may not be scalable. 
Exploration of system structure becomes important to reduce the complexity of the design problem.
Results: In this paper, we deduced a mathematical model which can simplify the serial structure and parallel structure 
of biological pathway for synergy evaluation of drug combinations. We demonstrated in steady state the sign of the 
synergism assessment factor derivative of the original system can be predicted by the sign of its simplified system. In 
addition, we analyzed the influence of feedback structure on survival ratio of the serial structure. We provided a 
sufficient condition under which the combination effect could be maintained. Furthermore, we applied our method to 
find three synergistic drug combinations on tumor necrosis factor α-induced NFκB pathway and subsequently verified 
by the cell experiment.
Conclusions: We identified several structural properties underlying the Bliss independence criterion, and developed a 
systematic simplification framework for drug combiation desgin by combining simulation and system reaction 
network topology analysis. We hope that this work can provide insights to tackle the challenging problem of 
assessment of combinational drug therapy effect in a large scale signaling pathway. And hopefully in the future our 
method could be expanded to more general criteria.
Background
Drug combination therapy is commonly used in clinical
practice [1-3]. For example, herbal remedies in traditional
Chinese medicine are believed to have synergism effect
[4,5]. How to define the drug synergism has been a long-
standing controversy amongst pharmacologists, toxicolo-
gists and biologists [6,7]. Among existing methods, under
the assumption that two drugs acting by independent
mechanisms, Bliss independence model is used to define
combined effect of two drugs [8]; given that two similar
drugs competitively acting on a target, Loewe additivity
model is used to predict the combined effect of two drugs
[9]. Chou-Talalay further proposed the Combination
Index (CI) theorem, serving as a general expression and
quantification of drug interaction based on the mass-
action law in biophysics and biochemistry [10-12]. These
models are widely used in in-vitro and in-silico experi-
ments for drug targets design and dose-response rela-
tionship analysis to instruct the selection of drugs and
design of combination scheme [13-15]. Although
improvements in the application scope and sensitivity of
synergy evaluation techniques allow a greater exploita-
tion of drug combination studies, it is unlikely that exper-
imental techniques will be sufficient to completely screen
the vast space of drug combinations in a cost-effective
and timely manner. Hence, finding a way to delimit this
space and obtain a manageable set of synergistic combi-
nations is still an ongoing challenge.
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To meet this challenge, we present a new method devel-
oped from the original Bliss independence criterion to
analyze the relationship between structures and effects
for combinational drug targets design from a mathemati-
cal aspect. Since Bliss model is relatively simple and still
widely used by some researchers recently [16-18], we
start our studies from this simple model and operation-
ally provide a combination effect assessment index
inspired by the Combination Index theorem [10-12].
With a foundational property of this index, the structure
information could be used to help the analysis of drug
combinational effects and design of combiantional drug
targets. Under this frame, we study two classic structures
(serial and parallel structures) in biological signaling sys-
tems and propose simplification rules which are helpful
for analyzing drug combination effects on the original
system. Furthermore, analysis of the feedback structures,
which is also very common in signaling pathways, is con-
ducted as an expansion to an original structures without
feedback. The usefulness of all the results is demon-
strated by numerical experiments.
As a concrete example, we applied our method to an
inflammatory angiogenesis-related pathway, the tumor
necrosis factor α (TNF-α)-induced NFκB pathway. The
comprehensive research of this pathway has accumulated
abundant exprimental data. This allows us to construct a
TNF-α-induced NFκB pathway model. Here, we further
extended previous model to endothelial cells to construct
a more accurate model for drug efficacy prediction. With
this new NFκB model in hand, we simualted the com-
bined effects of three important inhibitors, namely Alde-
hyde, Geldanamycin and PS-1145, in NFκB pathway. The
simulation results suggested that three inhibitor combi-
nations yeilded significant synergism and were validated
the simulated results by cell experiments.
Methods
Original Bliss Independence Criterion
Bliss independence [8] or fractional product method [19]
is the index for calculating the expected dose-response
relationship for drug combination therapy as compared
to mono-therapy. It assumes that the two inhibitors act
via independent mechanisms. Then drug combination
can be represented as the union of two probabilistically
independent events. And this criterion is identical to the
mutually non-exclusive case [20]. The combined effect of
two inhibitors (FUA) is computed as the product of indi-
vidual effects of the two inhibitors, FUA1 and FUA2.
where FUA is the remaining enzyme activity (fractional
unaffected).
Based on the definition, FUA is the expected combined
effect. If the actual combined effect of the two inhibitors
is equal to FUA, it is additive effect case and there is no
interaction between the two inhibitors. If the actual com-
bined effect is lower than FUA, it is called antagonism. If
the actual combined effect is higher than FUA, it is called
synergism which leads many possible favorable outcomes
like increasing or maintaining drug efficacy as decreasing
dosage and provides fundations to the combination ther-
apy [20].
Survival ratio
We use survival ratio as representation of the effect (frac-
tional unaffected) and define it as the ratio of component
concentrations before and after intervention:
where a, b are parameters that could be affected. Often
they have relationship with the inhibitor doses. a0 and b0
represent the normal values, which are the values before
being inhibited; a and b represent the values after being
inhibited. The output of a system is usually defined as the
concentration of some components.
Inspired by the Combination Index theorem offered by
Chou-Talalay [10,11], here we introduce an operational
concept, "Synergism Assessment Factor", for addressing
the interaction of drug combination. Then the Bliss inde-
pendence criterion could be rewritten as:
Where r(a, b) is the actual combined effect and r(a0,
b)·r(a, b0) is the expect combined effect calculated by the
product of individual effects. S  denotes Synergism
Assessment Factor. Eq. 3 is identical to the fraction prod-
uct equation of Webb [19] and the mutually non-exclu-
sive case in [21]. Compared with the critical point (CI =
1) of Chou-Talalay's Combination Index, we used S = 0 as
the critical point to determine whether there is sysnergis-
tic effect. Under the first order mutually non-exclusive
case, using Eq.3 will get the same conclusion on combina-
tion effect as using Combination Index.
Survival ratios of individual invention and combined
invention can be measured through in-vitro or in-silico
experiments, so it is convenient to verify whether syner-
gism is generated under specific drug combination with
this criterion [22]. Therefore, it is widely used in combi-
nation therapy design [16-18]. However, it is hard to pre-
FFF UA UA UA =× 12 (1)
rab
output a b
output a b
(,) =
(,)
( 0, 0)
(2)
S rab ra b rab =(,) ( ,) (, )
0
0
0
00 −⋅
<
=
>
  
Synergism
Additive effe
Ant tagonism
⎧
⎨
⎪
⎩
⎪Yan et al. BMC Systems Biology 2010, 4:50
http://www.biomedcentral.com/1752-0509/4/50
Page 3 of 12
dict the combined effect of two inhibitors without
experiments according to this model itself. In order to
predict the proper dose range to generate synergism, we
have to gain the dose-response relationship. The dose-
response relationship could be get through series of in-
vitro  experiments costly under different doses. Some-
times the dose-response relationship is assumed to have
some special form like Hill equation to reduce the experi-
ment costs [22]. It is feasible when possible targets num-
ber is small. As the targets number increases, it will face
the combinatorial explosion to choose targets and proper
doses, and the experiments cost also increases. New
method to narrow down the possibilities in searching tar-
gets and doses generating synergism by experiments
needs to be developed.
Extended Bliss Independence Criterion
Here, we extend Bliss independence criterion with the
sensitivity information of Synergism Assessment Factor.
The system with some special structures could be simpli-
fied for synergism-generating targets with doses based on
this criterion. We define:
where, r(a, b) is the survival ratio of the system; a and b
are parameters affected by inhibitor (ususally the reaction
velocity constants [13]), a0 and b0 are separately the value
of unaffected. Here DS denotes Synergism Assessment
Factor Derivative. Actually DS is the second-order patial
derivative of S. Our criterion is stated as
This criterion is based on the following observations.
The connection between DS and S is:
It is easy to see that if DS < 0 (for the interested drug
dose ranges), then S is guaranteed to be smaller than 0. It
means that synergism is generated over the parameter
ranges (a0, a), (b0, b). Similarly, the condition to generate
antagonism is also intuitive.
This extended Bliss independence criterion could be
seen as the derivative form of the original Bliss indepen-
dence criterion.
Fundamental property of synergism assessment factor 
derivative
The extended Bliss independence criterion introduced in
Eq. 5 enables us to find special structures of systems that
simplification is possible for synergism-generating targets
with doses. Here we provide a basic property of the syn-
ergism assessment factor derivative DS. It is the founda-
tion for our main results.
If the inhibitors individually affect some intermediate
processes, then the inhibition on these processes could be
taken as directly on the products of these processes. That
is to say, x = Φ (a) is the product of the process where
parameter a is affected; y = Ψ (b) is the product of the
process where parameter b is affected. Then the inhibi-
tion effects to the output of system on a and b could be
taken as on x and y. The analysis of combination effects
on the original system could then be limited on a simpli-
fied system with x and y as parameters.
Lemma 1
a and b are system parameters that will be affected by
inhibitors. a is of processes that will produce product x (x
= Φ (a)), and b is of processes that will produce product y
(y = Ψ (b)). Then the synergism assessment factor deriva-
tive DS of the original system satisfies
Where ,  x = Φ (a), y =
Ψ (b), x0 = Φ (a0), y0 = Ψ (b0). Details of proof are given in
Additional file 1.
DS is the synergism assessment factor derivative of the
original system while DS' could be seen as that of a sim-
plified system. Usually the signs of derivatives   and 
are easy to know, then the sign of DS could be decided on
the sign of DS'; and we only need to analyze the sign of
DS', which is the combination effect of the simplified sys-
tem. Meanwhile, with the sensitivity information of inter-
mediate process to inhibitors, we can compare the DS
values of different inhibitors that have the same structure
properties and select proper drug combinations with syn-
ergism property.
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Methods for the case study of TNF-α-induced NFκB 
pathway
Model construction and drug selection (see details in Results 
and Discussion)
We constructed the TNF-α-induced NFκB pathway in
Human umbilical vein endothelial cell (HUVEC). The
model was developed based on literatures [23-26]. We
tweaked the parameter values in terms of the experimen-
tal data derived from HUVEC [27]. The new pathway
model yielded a better simulation of NFκB activation in
HUVEC. The details of Ordinary Differential Equations
(ODEs) model of the NFκB pathway could be found in the
Additional file 2.
According to simulation results, we made a short list of
NFκB activity inhibitors covering three key nodes in the
pathway including Proteasome Inhibitor II Aldehyde,
HSP90 inhibitor Geldanamycin and IKK-β inhibitor PS-
1145 (Additional file 3, Table S5). To determine the doses
of these inhibitors in our experiment, we refer to the rela-
tive IC50 values of these inhibitors taken from the pub-
lished experimental and clinical data [28-30]. In our
model, Intercellular cell adhesion molecule-1 (ICAM-1)
is very sensitive to TNF-α stimulation. It is directly regu-
lated by activated NFκB and become output index of
downstream of this pathway.
In the simulation, the changes on relative reaction
velocity constants were taken as the inhibition influence
on the targets [31,32]. According to Lemma 1, we simpli-
fied the system and considered the synergism assessment
factor on this simplified system. Through simulations
with changing the reaction velocity constants in a wide
range that responded to a wide dose range, the drug com-
bination effects of the simplified system were gained.
Additional file 3 provides a detailed description of the
simulation algorithm.
Cell culture and reagents
To evaluate the computational results of our method, we
conducted a cell experiment as follows. HUVECs were
isolated from freshly obtained human umbilical cords by
established methods [33]. The cells were grown onto gel-
atin-coated 10 cm2 culture dishes in a standard endothe-
lial cell medium (ECM) (ScienCell Research
Laboratories). ECM consists of 500 ml of basal medium,
25 ml of fetal bovine serum (FBS), 5 ml of endothelial cell
growth supplement (ECGS) and 5 ml of penicillin/strep-
tomycin solution (P/S). Cells used for this study were
from passages 4 to 8 in ECM at 37°C in a 5% CO2/humid-
ified air incubator and starved for 6 hours in 0.1% FBS
medium before each assay. All experiments were carried
out when the cells were 80% confluent. Proteasome
Inhibitor II Aldehyde and HSP90 inhibitor Geldanamycin
w e r e  p u r c h a s e d  f r o m  A l e x i s  B i o c h e m i c a l s  ( S a n  D i e g o ,
CA). IκB kinase (IKK-β) inhibitor PS-1145 was from
Sigma-Aldrich (St. Louis, MO). These inhibitors were
dissolved in DMSO and stored at -20°C until use. The
recombinant human TNF-α (rh-TNF-α) protein was pur-
chased from Cell Signaling T echnology Inc. (CST , Bev-
erly, MA). Antibodies to ICAM-1 and β-actin were
obtained from CST.
Western blotting
To detect the effect of three combinations on output
index of this pathway, ICAM-1 directly regulated by
NFκB was investigated by western blotting as follows.
HUVECs were treated with 100 nM Aldehyde, 100 nM
Geldanamycin, 100 nM PS-1145 and various combina-
tions of Aldehyde, Geldanamycin and PS-1145 at the
dose of 100 nM for 2 hours followed by 10 ng/ml TNF-α.
After 6 hours of treatment, whole-cell extracts from
treated cells and immunoblotting were prepared as previ-
ously described [34]. Whole cell lysates were subjected to
SDS-PAGE 10% gels. Proteins were transferred to nitro-
cellulose blotting membranes (Bio-Rad Laboratories,
Hercules, CA), and immunoblotted 4°C overnight with
anti-ICAM-1 and anti-β-actin Abs (typically 1:1,000 dilu-
tion) followed by secondary antibody conjugated with
horseradish peroxidase (1:10,000 dilution). The SuperSig-
nal® West Dura (Thermo Fisher Scientific, Rockford, Ill,
USA) was used for detection according to the manufac-
turer's instruction.
Results and Discussion
Most signaling pathways are constructed from three
types of structures - serial, parallel and feedback, so our
study will be focusing on these three structures. Based on
Lemma 1, the simplifications of serial structures and par-
allel structures are studied. We also analyze the influence
of feedback structure on serial structures. Numerical
examples are also given; the simulation results of both
original and simplified systems showed potency of the
method on analyzing the combination effects. All these
structures and figures are from Fitzgerald's work [1].
Simplification rule for serial structure
In Figure 1, A activates B, then B activates C. The concen-
tration of activated C is the output of this system. The
sequential activation processes construct a typical serial
structure. To illustrate the drug combination effects, we
designate that I1 and I2 are inhibitors affecting the two
activation processes separately.
Corollary 1
The sign of the synergism assessment factor derivative
DS of original serial structure in Figure 1 is opposite to
the sign of the synergism assessment factor derivative DS'
of the simplified structure (shaded area in Figure 1). That
is to say,
sign DS sign DS () = ( ) − ′Yan et al. BMC Systems Biology 2010, 4:50
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Simplification rule for parallel structure
In Figure 2, there are parallel activation processes: A1
activates B1, A2 activates B2. As in serial structure, I1 and
I2 are inhibitors affecting those two activation processes
separately. Both B1 and B2 can activate C. The output of
this system is the concentration of activated C. The rela-
tion between B1 and B2 could be demonstrated as logic
OR.
Corollary 2
The sign of the synergism assessment factor derivative
DS of original parallel structure in Figure 2 is the same as
the sign of the synergism assessment factor derivative DS'
of the simplified structure (shaded area in Figure 2). That
is to say,
By Corollary 1 and 2, whether the simplified systems
could generate synergism under equivalent inhibition can
help to determine whether the original systems can gen-
erate synergism effect under actual inhibition (see details
of proofs in Additional file 1). In Figure 1, the original
serial structure under I1 and I2 inhibition can be simpli-
fied as the system (shaded) under equivalent I1' and I2
inhibition from the view of combination effects; It is the
same to simplify the original parallel structure under I1
and I2 inhibition as a system under equivalent I1' and I2'
inhibition. This could simplify the system structures,
meanwhile simplify the drug combination analysis.
Besides, it becomes easier to find drug combinations that
could generate synergism on the systems based on these
conclusions.
Combination effect preservation rule for systems with 
feedback
Feedback structures are common regulatory structures in
biological systems, especially in signaling pathways. Posi-
tive and negative feedback structures could shape the sig-
naling responses in time and space [35], like
performancing as oscillators or bistable switches. Feed-
back structures increase the complexity of system struc-
tures, and make it more difficult to analyze the drug
sign DS sign DS () = ( ) ′
Figure 1 Serial structure. The left subfigure illustrate the general serial structure. The right subfigure is an example from [1]. The shaded areas are the 
simplified systems. Based on the simplification rules the virtual inhibitors on the simplified systems in this example target on the reaction B-P+CTC-P 
(or it also could be seen as target on component B-P) and component C.Yan et al. BMC Systems Biology 2010, 4:50
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combination effects on the systems. From the viewpoint
of drug combination therapy, sometimes we just need to
know how the feedback structures influence the drug
combination effects.
Considering an original system without feedback loop
that can generate synergism effect under some drug com-
binations (left subfigure in Figure 3), if after adding a
feedback loop (right subfigure in Figure 3), the output of
the new system decreases compared to that of original
system, then the feedback loop can be believed that it
strengthens the drug combination effects. Upon that, it
could only consider combination effect analysis on the
original system.
In general feedback structures (as shown in right sub-
figure in Figure 3) and the system without the feedback
loop can be modeled by Ordinary Differential Equations
(ODEs) separately as
Lemma 2
Adding feedback loop to a system will not decrease the
drug combination effects of the original system if
. That is,
1) Negative feedback (g(·) <0), and   >0
or
2) Positive feedback (g(·) <0), and   <0 is satisfied.
Details of proof are given in Additional file 4.
Examples of serial structure and parallel structure
We adapted numerical examples in [1] as shown in Figure
1 and Figure 2 respectively to verify the Corollary 1 and 2
above. All parameters are referred to [1]. In addition, all
the reactions are modeled as Michaelis-Menten equa-
tions. Direct evaluation of the synergism asscessment fac-
tor S by simulation leads to the results shown in Figure 4.
In Figure 4, left figure shows the results of serial struc-
ture and right figure shows the results of parallel struc-
ture. The blue curves referred to the S curves recovered
from results of the simplified systems, while the red lines
referred to the results of the original systems. It is obvious
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Figure 2 Parallel structure. The left subfigure illustrate the general parallel structure. The right subfigure is an example from [1]. The shaded areas 
are the simplified systems. Based on the simplification rules the virtual inhibitors on the simplified systems in this example target on the reactions B1-
P+CTC-P (or it also could be seen as target on component B1-P) and B2-P+CTC-P (or target on component B2-P).Yan et al. BMC Systems Biology 2010, 4:50
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that the recovered S curves agreed with the original S
curves. Actually, the S curve of the simplified serial sys-
tem has opposite sign to that of the original serial system.
S curves with negative signs indicate that both the orig-
i n a l  s e r i a l  a n d  p a r a l l e l  s t r u c t u r e s  g e n e r a t e  s y n e r g i s t i c
effect. In left subfigure the absolute values of S  are
smaller (10-3 order) than those of the S in right subfigure
(10-1 order). Combination therapy of the parallel struc-
ture could be more effective. These results are coninci-
dent with the results in [1]. As a comparison from these
results, the new method enables us to evaluate the combi-
nation effects of original systems by analyzing the effects
of the corresponding simplified systems.
An example of negative feedback structure
Figure 5 from [1] shows the example of negative feedback
structure. This negative feedback system is constructed
based on the serial system in Figure 1. From the results in
[1] the influence of feedback on combination effects is
verified to have nonnegative impact under the condition
1) in Lemma 2.
Based on the ODEs of the serial structure, the ODEs of
this feedback structure are as follows:
In the model, x1 and x2 are concentrations of B-P and C-
P (activated C) respectively. x2 is the output of the system.
x1t and x2t are initial concentrations of B and C respec-
tively.  R  is the concentration of A. Km1  and  Km2  are
Michaelis-Menten constants of the BTB-P and CTC-P
activation and are affected by I1 and I2, respectively. Km5
are Michaelis-Menten constants of B-PTB activation
mediated by C-P. From the simulation results in [1], it is
obvious that the output of feedback structure example is
smaller than the output of serial structure. This compari-
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Figure 3 Illustration of feedback structures. R is the input of x. y is the output of the system. f is the intermediate process from x to y. g is the feed-
back function. a and b are affected parameters.Yan et al. BMC Systems Biology 2010, 4:50
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son verified Lemma 2 that feedback loop can strengthen
the drug combination effects.
It should be pionted out, although our method leads to
simplified systems, that does not mean the analysis of the
simplified systems is easy. Usually simulations or experi-
ments are still needed for analyzing these systems due to
their complex dynamics [14,36-38]. Our method also
relies on the faithful modeling of the systems which may
not be trivial since identifying system structure in general
is still a challenging work [39-41].
Results and discussion for the case study of TNF-α-induced 
NFκB pathway
TNF-α is both a pro-inflammation cytokine and a pro-
angiogenic factor [42]. It is responsible for inflammatory
angiogenesis and tumorigenesis. The induction of NFκB
signaling pathway by TNF-α can regulate the transcrip-
tional expression of several genes in vascular endothelial
cells that lead to angiogenesis [42]. Several standard drug
targets such as HSP90 and IKK-β are among the key mol-
ecules involved in the pathway responsible for generating
angiogenic factors. However, essentially all single-target
inhibitors have low therapeutic effects in inflammatory
and angiogenic diseases. To find more efficient drug
combination solutions, we constructed the model of an
inflammatory angiogenesis-related pathway, the TNF-α-
induced NFκB pathway (Figure 6A) and employed our
method in this paper to search for synergistic drug com-
bination solutions within this pathway model.
As a result of our method, IκB degradation proteasome,
HSP90 and IKK-β as important targets in the TNF-α-
induced NFκB pathway are selected. In the simulation,
changes on the relative reaction velocity constants were
taken as the inhibition influence on targets. It should be
pointed out that Geldanamycin as a HSP90 inhibitor dose
not target RIP1 directly but could indirectly regulate the
binding rate of RIP1, so we changed the reaction velocity
constants of RIP1 binding with TNFR1 complex. The
change ratio of the reaction velocity constants ranged
from 0.9 to 0.0001 fold to cover a wide dose range.
As shown in Figure 6B, the TNF-α-induced NFκB path-
way has a serial structure with feedback. The three tar-
gets locate on the serial path (RIP1 and IKK-β) and
feedback path (IκB degradation), especially IKK-β is on
the joint of serial path and feedback path. Since TRAF2-
RIP1-TRADD-TNFR1-TNF-α activates IKK-β, the inhi-
bition effect on RIP1 could be seen as finally acted on
IKK-β. According to Lemma 1, the system could be sim-
plified as the dashed box area in Figure 6A. The corre-
sponding reactions inhibited by the three inhibitors in
original and simplified systems were shown in Table 1.
We then employed our method to calculate the synergism
assessment factor on the simplified system. The sign of
synergism assessment factor decides whether there is
Figure 4 S curves of Figure 1 and 2. In the simulation, we adopted the same doses of both inhibitors like [1]. The left subfigure is the simulation 
results of the serial structure in Figure 1. The right subfigure is the simulation results of the parallel structure in Figure 2. The S curves of original systems 
are in red. The blue curves are the S curves recovered from the results of simplified systems based on Lemma 1 and the two corollaries. In fact the S 
curve of the simplified serial system has opposite sign to that of the original serial system. Obviously the S curves recovered agreed with the original 
S curves. The signs of S curves are negative showing the synergistic effect of the serial and parallel structures. In left subfigure the absolute values of S 
are much small (10-3 order) to those of the S in right subfigure (10-1 order). Combination therapy of the parallel structure could be more effective. These 
results are conincident with the results in [1].Yan et al. BMC Systems Biology 2010, 4:50
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synergistic effect or not. The value of synergism assess-
ment factor reflects the efficacy extent of drug combina-
tion from Aldehyde, Geldanamycin and PS-1145 (shown
in Figure 6B). We screened out the synergistic drug com-
binations according to the sign of synergism assessment
factor in simplified system. Then we did the simulation
on the original system for the synergistic drug combina-
tions. The simulation results are shown in Table 2. It
shows that all the three drug combinations could gener-
ate synergistic effect. And the signs of synergism assess-
ment factors in simplified system were consistent with
those of the synergism assessment factors in original sys-
tem.
ICAM-1, an intercellular adhesion molecule expressed
in endothelial cells, is a common cellular readout of TNF-
α induced signaling pathway [43]. To verify the simula-
tion results, we observed the effect of Aldehyde, Geldana-
mycin, PS-1145 and related combinations on ICAM-1
expression level by western blotting analysis. In the
experiment, we used Bliss independent model to assess
whether three combinations induced synergistic inhibi-
tion effect on ICAM-1 expression. As shown in Figure 6C
and Figure 6D, all the three drug combinations generate
synergistic effect. Taken together, this result suggests that
the synergistic combinations predicted by our method
are qualitatively consistent with the experimental obser-
vations. Currently, the method can only make qualitative
prediction on drug combinational effects. This still could
provide some clues for drug combination design based on
mechanisms. Besides, as the model we provided here is
specific for TNF-α-induced NFκB pathway in HUVEC,
the general applicability of our method still needs further
investigation.
Conclusions
In this paper we presented a new method based on an
extended Bliss independence criterion to analyze the
relationship between structures and effects for combina-
tion drug targets design from a mathematical aspect. We
analyzed two classic structures, serial structure and par-
allel structure, and showed in steady state the sign of the
synergism assessment factor derivative of the original
system can be predicted by the sign of its simplified sys-
tem. In addition, we analyzed the influence of feedback
structure on survival ratio of the system, and showed that
the feedback structure could not destroy the drug combi-
nation effect of the system without feedback under some
conditions. We demonstrated by numerical examples that
these results are useful for reducing the amount of com-
putatioal load if system reaction network topology
knowledge is available. In the case study, the effects of
inhibitor combinations predicted by our method were
experimentally validated by measuring the output
(ICAM-1 expression) of TNF-α-induced NFκB pathway.
Figure 5 Negative feedback structure. This system with negative feedback loop (from [1]) is constructed based on the serial system in Figure 1 by 
adding a feedback loop (orange color) which is from the output C-P to the activation of B to the serial structure. The output of this system is still the 
concentration of activation C.Yan et al. BMC Systems Biology 2010, 4:50
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Figure 6 Case study of TNF-α-induced NFκB pathway. A. The kinetic model of TNF-α-induced NFκB pathway. The dashed box area indicates the 
simplified system. B. Biological schematic of TNF-α-induced NFκB pathway. Not all arrows represent direct physical interactions. Drugs used in this 
study and their key targets are highlighted. C. HUVECs were pretreated with three combinations at the same concentration 100 nM for 2 hours before 
being stimulated with 10 ng/ml TNF-α for 6 hours. Cells were lysed and output signaling protein was probed by western blotting. The level of β-actin 
was used as an internal control for normalization. The gray values are recorded at the bottom. D. Ratio of ICAM-1 to β-actin was determined with den-
sitometry. C, control, T, 10 ng/ml TNF-α, G, Geldanamycin, A, Aldehyde, P, PS-1145.
Table 1: Comparison of reactions inhibited by drugs in original and simplified systems.
Inhibitors Corresponding reactions 
in original system
Corresponding reactions 
in simplified system
Geldanamycin RIP1 binding with TNFR1 complex IKKK-P activates IKK-β
PS-1145 IKK-β-P phosphorylates IκB IKK-β-P phosphorylates IκB
Aldehyde IκB degradation IκB degradation
In the simulation, we simplified the system according to Lemma 1. Here we list the corresponding reactions inhibited by the three inhibitors 
in original and simplified systems.Yan et al. BMC Systems Biology 2010, 4:50
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Hopefully, this work can provide some insights to tackle
the challenging problem of assessment of combination
drug therapy effct in a large scale signaling pathways. As
we point out, Bliss model is relatively simple, so in this
paper we focused on this simple model. With deep under-
standing of dose-effect curves, we hope in the future our
method could be expanded to more general criteria such
as the law of mass action [10-12,21].
Note
In the following figures (Figure 1, 2, 3, 4, 5), A, B, C, A1,
A2, B1, B2 are components of the systems, I1 and I2 are
inhibitors. The shaded areas represent simplified systems
for the original systems. I1' and I2' are virtual inhibitors on
the simplified systems equivalent to I1 and I2 .
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